个人信息
Personal Information
联系方式
Contact Information
个人简介
Personal Profile
赵双涛，首都医科大学附属北京胸科医院乳腺诊疗中心，副主任医师，研究员，教授，博士生导师。
2016年7月于南开大学获得肿瘤学博士学位。2016年7月至2018年7月在北京协和医学院中国医学科学院肿瘤医院从事肿瘤学博士后研究，2018年10月至2020年10月在美国MDAnderson癌症中心从事肿瘤学博士后研究，2021年12月入选国家级人才计划，主攻方向为乳腺癌的精准诊治与个体化治疗，人工智能与肿瘤大数据处理与分析，多组学综合运用临床转化研究。
专业擅长：
从医十余年，目前主要致力于乳腺良恶性肿瘤外科诊治和个体化治疗，尤其是乳腺结节及乳头溢液的早诊早治，以及乳腺癌的外科手术治疗、术前新辅助化疗、术后辅助化疗、靶向治疗、内分泌治疗及免疫治疗等。
科研成果：
先后参与国家重点基础研究发展计划(973计划)、国家高技术研究与发展计划(863计划)、美国抗癌“登月计划”及国家自然科学基金面上项目等多项研究，发表SCI论文40余篇，累计IF400以上，申请国家及国际发明专利3项。
教学情况：
首都医科大学肿瘤学教授、博士生导师，北京市结核病胸部肿瘤研究所外科学硕士生导师、免疫学博士生导师，北京工业大学电子信息(软件工程领域)专业硕士生导师，目前培养硕士研究生12人、博士研究生5人。
社会兼职：
北京围手术期医学研究会乳腺外科专业委员会委员
1）医疗大数据处理与分析研究，国家级人才项目，2021年12月至2025年12月，主持课题。
2）乳腺癌的影像语义分割及分子分型特征基因筛查方法研究，国家自然科学基金，2021年01月至2024年12月，参与课题。
代表性研究成果：
1）Zhao S*, Kanagal-Shamanna R*,Navsaria L, Chi Young OK, Zhang S, Nomie K, Han G, Hao D, Hill HA, Jiang C, YaoY, Nastoupil L, Westin J, Fayad L, Nair R, Steiner R, Ahmed S, Samaniego F,Iyer SP, Oriabure O, Chen W, Song X, Zhang J, Badillo M, Moghrabi O, Aranda J,Tang G, Yin CC, Patel K, Medeiros LJ, Li S, Vega F, Thirumurthi S, Xu G,Neelapu S, Flowers CR, Romaguera J, Fowler N, Wang L, Wang ML, Jain P*✉️. Efficacy ofvenetoclax in high risk relapsed mantle cell lymphoma (MCL) - outcomes andmutation profile from venetoclax resistant MCL patients. Am J Hematol, 2020.
2）Bo Liu*,Xinchan Ji, Jinmeng Li, Nian Zhu, Junqi Long, Xujie Zhuang, Huina Wang, LujiaLi, Yuhaoran Chen, Shuangtao Zhao✉️.Integrative analysis identifies three molecular subsets inovarian cancer. Clin Transl Med. 2022 Sep;12(9):e1029.doi:10.1002/ctm2.1029.
3) Zhao S*, RuipingWang , Shumei Song , Makoto Kobayashi , Dapeng Hao , Guangchun Han , XingzhiSong , Jianhua Zhang , Melissa Pool Pizzi , Namita Shanbhag , Andrew Futreal ,Brian Badgwell , Kazuto Harada , George A Calin , Jody Vykoukal , Chuan-Yih Yu, Hiroyuki Katayama , Samir Hanash✉️, Linghua Wang✉️, Jaffer AAjani✉️. ProteogenomicLandscape of Gastric Adenocarcinoma Peritoneal Metastases. iScience. 2023.26,106913.
4）Huina Wang*, Bo Liu*, Junqi Long, Jiangyong Yu,Xinchan Ji, Jinmeng Li, Nian Zhu, Xujie Zhuang, Lujia Li, Yuhaoran Chen,Zhidong Liu, Shu Wang, Shuangtao Zhao✉️. Integrative Analysis Identifies Two Molecular andClinical Subsets in Luminal B Breast Cancer. iScience. 2023July 26, 107466.
5) Jiaxiang Liu*, Shuangtao Zhao*,Chenxuan Yang, Li Ma, Qixi Wu, Xiangzhi Meng, Bo Zheng, Changyuan Guo, KexinFeng, Qingyao Shang, Jiaqi Liu, Jie Wang, Jingbo Zhang, Guangyu Shan, Bing Xu,Yueping Liu, Jianming Ying, Xin Wang✉️, Xiang Wang✉️.Establishmentand validation of a multigene model to predict the risk of relapse in hormonereceptor-positive early-stage Chinese breast cancer patients. Chin Med J(Engl).2023 Jan 20;136(2):184-193.
6) JiangyongYu*, ShuangtaoZhao*, ZheSu, ChengliSong, LihongWu, JingboWang, NanBi, LvhuaWang✉️(2022). Whole exome analysis reveals the genomic profiling related tochemo‐resistance in Chinese population with limited‐disease small cell lungcancer. Cancer Medicine.2022;00:1-16. doi: 10.1002/cam4.4950.
7) Mengyao Xu*,Shan Huang*,JiahuiChen,Wanxue Xu, Rong Xiang, Yongjun Piao✉️,Shuangtao Zhao✉️. Cytotoxic lymphocytes-related gene ITK from a systematicCRISPR screen could predict prognosis of ovarian cancer patient with distantmetastasis. Journal ofTranslational Medicine19.no.1(2021):1-12.
8) Zhao S*, Shen W*, Yu J, Wang L✉️. TBX21 predicts prognosis of patients and drives cancer stemcell maintenance via the TBX21–IL-4 pathway in lung adenocarcinoma. Stemcell research & therapy. 2018 Dec;9(1):89.
9) Shen W*, Zhang X, Du R, Fan Y, Luo D, Bao Y,Yang W, Luo N✉️, LuoY✉️, ZhaoS✉️. ICAM3 mediates tumormetastasis via a LFA-1-ICAM3-ERM dependent manner. Biochimica etBiophysica Acta (BBA)-Molecular Basis of Disease. 2018 Aug1;1864(8):2566-78.
10) Zhao S*, Yu J, Wang L✉️. Machine Learning BasedPrediction of Brain Metastasis of Patients with IIIA-N2 Lung Adenocarcinoma bya Three-miRNA Signature. Translational oncology. 2018 Feb1;11(1):157-67.
11）Zhao S*, Shen W*,Du R, Luo X, Yu J, Zhou W, Dong X, Gao R, Wang C, Yang H, Wang S✉️. Three inflammation‐relatedgenes could predict risk in prognosis and metastasis of patients with breastcancer. Cancer medicine. 2019 Feb;8(2):593-605.
12）Zhao S*, Dong X, Shen W, Ye Z and Xiang R✉️.Machine learning‐based classification of diffuse large B‐cell lymphoma patientsby eight gene expression profiles. Cancermedicine. 2016 May;5(5):837-52.
13) Zhao S*, Bai N, Cui J, Xiang R✉️and Li N✉️. Prediction of survival of diffuse large B‐celllymphoma patients via the expression of three inflammatory genes. Cancer Medicine. 2016; 5(8):1950-1961.
14) Liu, B.*, Li, X.,Wang, H., Zhao, S✉️.,Li, J., Qu, G., & Wang, F. (2020). Retyping of triple‐negative breastcancer based on clustering method. Expert Systems, e12583.
15) Liu.B.*, Zhao,YL., Yang, B., Zhao, S✉️., Gu, R.T., A GastricCancer Recognition Algorithm on Gastric Pathological Sections Based onMSA-DenseNet. Concurrency and Computation Practice and Experience.2020.Nov;11(3):56-62.
16) Wang, M. L.*✉️, Jain, P., Zhao, S., Lee, H. J., Nastoupil,L., Fayad, L., ... & Mantle Cell Research Group. (2022).Ibrutinib–rituximab followed by R-HCVAD as frontline treatment for youngpatients (≤ 65 years) with mantle cell lymphoma (WINDOW-1): a single-arm, phase2 trial. The Lancet Oncology.
17) Jain,P.*, Zhao, S., Lee, H. J., Hill, H. A., Ok, C. Y.,Kanagal-Shamanna, R., ... & Wang, M. L✉️. (2022). Ibrutinib with rituximab in first-linetreatment of older patients with mantle cell lymphoma. Journal of ClinicalOncology, 40(2), 202-212.
18) Yang C*, Liu J, ZhaoS, Ying J, Liu Y, Ma L, Shang Q, Meng X, Feng K, Zheng B, Guo C, Wang X✉️,Wang X. Establishment and validation of a gasdermin signature to evaluate theimmune status and direct risk‐group classification in luminal‐B breast cancer. Clinicaland Translational Medicine. 2021 Nov;11(11).
19)Shen W*, Xie J*, Zhao S, Du R, Luo X, He H, JiangS, Hao N, Chen C, Guo C, Liu Y, Chen Y, Sun P, Yang S, Luo N, Xiang R, Luo Y✉️. ICAM3 mediates inflammatorysignaling to promote cancer cell stemness. Cancer Lett . 2018,422:29-43.
20)Bo Liu*, Huina Wang, Xin Wang, Junqi Long, Xujie Zhuang, Xinchan Ji,Nian Zhu, Jinmeng Li, Ting Gao, Xuehui Zhang, Jiangyong Yu, Shuangtao Zhao✉️. Four-gene signature based onmachine learning filtration could predict prognosis of patients with breastcancer. Expert Systems. 2022;e13157.
21) Chenxuan Yang*, Jiaxiang Liu*, Shuangtao Zhao,Qingyao Shang, Fei Ren, Kexin Feng, Ruixuan Zhang, Xiyu Kang, Xin Wang✉️, Xiang Wang. Infiltrating myeloid cell diversity determinesoncological characteristics and clinical outcomes in breast cancer. BreastCancer Research. 2023 Jun 7;25(1):63.
22) Xujie Zhuang*, Bo Liu*, Junqi Long, Huina Wang ,Jiangyong Yu, Xinchan Ji, Jinmeng Li, Nian Zhu, Lujia Li, Yuhaoran Chen,Zhidong Liu, Shuangtao Zhao✉️.Machine-learning-based classification of diffuse largeB-cell lymphoma patients by a 7-mRNA signature enriched with immuneinfiltration and cell cycle. Clinical & Translational Oncology.2023, 1-15.
23) 嵌入式临床辅助决策系统V1.0. 杨合利; 鄢谢桥; 王轩; 崔传亮; 于江泳; 危志刚; 张扬子; 丁小胜; 赵双涛. 2021SR1444974, 原始取得, 全部权利, 2021-2-3 （软件著作权）
24) 乳腺癌诊断标志物基因及其筛查方法。赵双涛，刘志东，王慧娜，于江泳，徐蔚然。申请号：202310058165.3。国家发明专利，2023-02-04。
25) 乳腺癌诊断标志物基因及其筛查方法。赵双涛，刘志东，王慧娜，于江泳，徐蔚然。申请号：PCT/CN2023/098726。国际发明专利，2023-06-07。
26) 激素受体阳性乳腺癌患者术后复发风险评估试剂盒。王昕，刘佳祥，赵双涛，杨琛轩。专利号：ZL 2022 2 1942434.X。实用新型专利证书，2022-07-26。
文件上传中...
